LHC Group reported adjusted earnings per share (EPS) of 98 cents in the first quarter of 2019. The figure beat the Zacks Consensus Estimate of 90 cents and also surged 55.6% year over year.
The Zacks Rank #3 (Hold) company posted revenues worth $502.6 million in the quarter, which missed the Zacks Consensus Estimate by 1.7%. Revenues however shot up 72.7% on a year-over-year basis.
Q1 Highlights
In the quarter under review, total growth in home health admissions was 76.3% year over year and organic growth was 5.7%.
Total growth in home health revenues was 77.4% year over year and organic growth was 7%. Meanwhile, growth in hospice admissions was 13.1% year over year and organic growth was 6.2%.
Notably, the company realized approximately $7.4 million in pre-tax synergies in the first quarter from its acquisition of Almost Family. In the reported quarter, the company agreed to acquire 18 home health, hospice or home and community-based services locations, all of which are hospital joint ventures.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
LHC Group reported adjusted earnings per share (EPS) of 98 cents in the first quarter of 2019. The figure beat the Zacks Consensus Estimate of 90 cents and also surged 55.6% year over year.
The Zacks Rank #3 (Hold) company posted revenues worth $502.6 million in the quarter, which missed the Zacks Consensus Estimate by 1.7%. Revenues however shot up 72.7% on a year-over-year basis.
Q1 Highlights
In the quarter under review, total growth in home health admissions was 76.3% year over year and organic growth was 5.7%.
Total growth in home health revenues was 77.4% year over year and organic growth was 7%. Meanwhile, growth in hospice admissions was 13.1% year over year and organic growth was 6.2%.
Notably, the company realized approximately $7.4 million in pre-tax synergies in the first quarter from its acquisition of Almost Family. In the reported quarter, the company agreed to acquire 18 home health, hospice or home and community-based services locations, all of which are hospital joint ventures.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SYK - FREE
Get the latest research report on CNMD - FREE
Get the latest research report on XRAY - FREE